Otsuka Pharmaceutical's world's first IgA nephrodisease-targeting biologic agent, sibelizumab injection, was included in the 2026 National Medical Insurance Drug List to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy at risk of disease progression.

Zhitongcaijing · 2d ago
Otsuka Pharmaceutical's world's first IgA nephrodisease-targeting biologic agent, sibelizumab injection, was included in the 2026 National Medical Insurance Drug List to reduce proteinuria in adult patients with primary immunoglobulin A nephropathy at risk of disease progression.